Prabir Roy-Chaudhury, MD
Dr. Roy-Chaudhury is a professor of Medicine at the University of Cincinnati and a specialist in the field of Nephrology & Hypertension. His clinical work focuses on kidney and kidney-pancreas transplantation while one of his main research interests is in the treatment of neointimal hyperplasia in dialysis access patients. He is actively involved in several clinical research trials, lectures extensively throughout the world, and has numerous publications.
Marc Glickman, MD
Dr. Glickman is a Fellow of the American College of Surgeons (FACS). He is the medical director of the Peripheral Vascular Laboratory at Chesapeake General Hospital as well as the medical director for Sentara's Southside hospitals' vascular services. Dr. Glickman has co-authored and published numerous vascular disease and vascular surgery articles and has presented papers to surgical societies around the world and as a result he is regularly invited to speak on the subject at national and international medical conferences.
E. John Harris, Jr., MD
Dr. Harris is a professor of Medicine in the Department of Vascular Surgery at Stanford University. His research interests are in the role of thrombosis in stimulating venous wall morphologic change. He has been involved in numerous clinical trials for peripheral artery disease as well as endovascular repair procedures for abdominal aortic aneurysms. He is a co-author on many publications and a lecturer at society meetings.
Ted Kohler, MD
Dr. Kohler is a Professor of Surgery at the University of Washington as well as the Chief of Peripheral Vascular Surgery at the Seattle VA Medical Center. His clinical interests are in Dialysis access surgery, peripheral vascular surgery, and Epidemiology. His research interests focus on hemodialysis vascular access dysfunction, intimal hyperplasia, and thrombosis. He is extremely well published and offers NanoVasc both a clinical and research perspective on vascular graft performance.
Mark Nathan, MD
Dr. Nathan is a practicing Interventional Cardiologist in the San Francisco bay area. He is medical director of the Cath lab and was trained at Cedar-Sinai in Los Angeles. With more than 25 years of clinical practice experience, he is an accomplished lecturer, an investigator in 10 different clinical trials, has conducted pioneering research in the use of ACE inhibitors in congestive heart failure and in thrombolytic therapy for acute myocardial infarction, and was an early adopter of office-based nuclear cardiology. He offers NanoVasc some broad insight into the world of intervention medicine.